The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

NEW YORK – Genentech on Tuesday said the Phase III SKYSCRAPER-01 trial of the anti-TIGIT antibody tiragolumab with its anti-PD-L1 drug Tecentriq (atezolizumab) in patients with PD-L1-high, locally ...

The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.

The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.

NEW YORK – Eisai on Tuesday said it has struck a research collaboration agreement with the National Center of Neurology and Psychiatry (NCNP), a healthcare and research organization in Tokyo, to ...